Orthotopic tumor models provide a clinically relevant, organ-specific tumor microenvironment (TME) to improve preclinical predictivity over subcutaneous alternatives. Generated by seeding tumor cells at the organ-specific site of the original tumor, orthotopic models mimic the primary lesion and establish better tumor, stroma, and immune component interactions than subcutaneous implantation.
This allows more human-disease relevant tumor development and progression, including spontaneous metastasis, recapitulating late-stage tumors. Orthotopic models therefore provide the ideal setting to:
Orthotopic metastatic models are most powerful when the disease is tracked in vivo in real time by optical imaging of luciferase-labeled tumor cells.
Figure 1: Luciferase-labeled model establishment by lentiviral transduction
Our collection of luciferase-labeled validated in vivo models allow you to non-invasively monitor the longitudinal growth of a tumor and to track tumor response to your treatment in real time, saving time and resources.
Our cutting edge imaging techniques and platforms include:
Our panel of orthotopic bioluminescent models include syngeneic as well as xenograft lines.
Table 1: Available bioluminescent models (additional models under development and can be developed upon client request)
*Client license required
Models provided by sponsor but the right of use has been granted (not fit for CFDA studies)